Catalyst Wire Dossier Catalyst Wire Dossier

REGN5668

· Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REGN5668, covering 2025-11-21 to 2025-11-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab [Phase 1, Phase 2]

See pricing